R&D sites in China, Denmark, India and US.
Approximately 5,650 employees
In 2015 Novo Nordisk’s R&D costs amounted to 14.6 billion Danish kroner, representing 13% of sales.
Every year, 15,000–25,000 patients in more than 50 countries take part in a Novo Nordisk clinical trial. Novo Nordisk's execution of clinical trials is among the best in the industry, and in March 2015 the company was ranked number one in CenterWatch's global survey on clinical trial site relationships.
Science Top Employer
Novo Nordisk has been ranked in the top five on the Science Careers Top Employers list since 2014.
For 12 consecutive years, Novo Nordisk has been ranked world-leading in the bioethics category of the Dow Jones Sustainability Index (DJSI).
Novo Nordisk collaborates with numerous biotech companies, including Genmab, Ablynx and XOMA, and world-class universities, including the University of Oxford (UK) and MIT (US), in order to accelerate innovation from partnerships to patients and attract top talents to its global R&D sites.
Since 2012, Novo Nordisk has been involved in the European Patients' Academy on Therapeutic Innovation (EUPATI), which aims to help patients be effective advocates, with meaningful involvement in areas such as drug discovery, planning and conducting clinical trials, and regulatory affairs.